Table 3.
Volunteer demographics
| Characteristic | n (%) |
|---|---|
| Male, n (%) | 15 (35%) |
| Age (yr) at enrollment, median (IQR) | 36 (22, 47) |
| Race or ethnic group, n (%) | |
| White | 26 (60%) |
| Black | 10 (23%) |
| Hispanic | 4 (9%) |
| Other | 3 (7%) |
| Unscheduled health care visits for asthma in previous 12 mo | 3 (7%) |
| Systemic steroid for asthma in past 12 mo | 5 (12%) |
| Daily use of short-acting β-agonist (MDI/nebulizer) | 3 (7%) |
| Daily use of anti-leukotriene | 6 (14%) |
| Age of asthma onset (yr), median (IQR) | 8 (3, 15) |
| Spirometry, median (IQR) | |
| FEV1, %predicted | 91 (83, 98) |
| FVC, %predicted | 101 (90, 109) |
| Tests, median (IQR) | |
| Calculated PC20, mg/ml | 2.06 (0.55, 4.31) |
| Exhaled NO,* ppb | 32.25 (16.75, 63.50) |
| Questionnaires, median (IQR), unless noted | |
| Multivariable apnea prediction score‡ (range 0–18) | 1 (0, 3) |
| Epworth score‡ (range 0–24) | 7 (5, 9) |
| Pittsburgh Sleep Quality Index‡ (range 0–21) | 6 (3, 7) |
| Asthma symptom utility index§ (range 0–1) | 0.89 (0.83, 0.94) |
| Asthma control test§ (range 5–25) | 21 (20, 23) |
| Sinonasal SNQ-6 score‡ (range 0–3) | 1 (1, 2) |
| Berlin score, high risk,† n (%) | 11 (26%) |
A total of 43 subjects were studied. MDI, metered-dose inhaler; IQR, interquartile range; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; PC20, provocative concentration that causes 20% fall in FEV1.
*
9 subjects missing exhaled NO.
†
1 subject missing Berlin score.
‡
Higher score indicates worse control.
§
Higher score indicates better control.